Monday, November 13, 2017 10:44:58 PM
Doreen McMorran (doreen@invisicare.com)
Hello Doreen,
Could you possible give some figures on what the license agreement could potentially bring in for revenue.
Is Canopy purchasing each individual unit, or will it be in bulk quantities where as they will package and formulate on their end.
With the DermSafe as well as the Canopy deal it would be great to see some numbers of what the cost/profit would be on orders. If just "Potential" revenues on
1000 units
100,000 units
1,000,000 units
if you could give some guidance in this form I believe it would translate better to potential investors.
Thanks for your time
Recent SKVI News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2023 05:05:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 07:11:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM